SCHEMBL8486338

SCHEMBL8486338

COC(=O)CC1c2ccccc2C2CN(C(=O)CCCBc3ccccn3)CCC12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 6/20 0.34
MAPK1 P28482 3/20 0.34
NOS2 P35228 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
KDM4E B2RXH2 3/20 0.32
TSHR P16473 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HSD17B10 Q99714 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
GRIN2B Q13224 1/20 0.31
MEN1 O00255 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8487183 0.84 ITGB3 (0.42) NPC1RAB9AALDH1A1NOS2SMN1; SMN2
SCHEMBL14195948 0.84 ITGB3 (0.42) NPC1RAB9AALDH1A1NOS2SMN1; SMN2
SCHEMBL14195947 0.84 ITGB3 (0.42) NPC1RAB9AALDH1A1NOS2SMN1; SMN2
SCHEMBL8485605 0.78 ALDH1A1 (0.34) NPC1RAB9AALDH1A1MAPK1BCHE
SCHEMBL14195945 0.74 ITGB3 (0.48) NOS2GRIN2B
SCHEMBL14195949 0.74 ITGB3 (0.48) NOS2GRIN2B
SCHEMBL4805768 0.74 ITGB3 (0.48) NOS2GRIN2B
SCHEMBL8497981 0.72 SLC6A2 (0.44)
SCHEMBL14195942 0.72 SLC6A2 (0.44)
SCHEMBL14195934 0.66 EGFR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506779-B1 (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina JANSSEN PHARMACEUTICA NV (BE) 2006-07-12 EP disclosed